TY  - JOUR 
AU  - Mosquera Orgueira, Adrián
AU  - Bao Pérez, Laura
AU  - Mosquera Torre, Alicia
AU  - Peleteiro Raindo, Andrés
AU  - Cid López, Miguel
AU  - Díaz Arias, José
AU  - Ferreiro Ferro, Roi
AU  - Antelo Rodríguez, Beatriz
AU  - González Pérez, Marta Sonia
AU  - Albors Ferreiro, Manuel
AU  - Alonso Vence, Natalia
AU  - Pérez Encinas, Manuel Mateo
AU  - Bello López, José Luis
AU  - Martinelli, Giovanni
AU  - Cerchione, Claudio
PY  - 2020
UR  - http://hdl.handle.net/20.500.11940/22862
AB  - [EN] Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene arise in 25-30% of all acute myeloid leukemia (AML) patients. These mutations lead to constitutive activation of the protein product and are divided in two broad types: internal tandem...
LA  - eng
KW  - Mutation
KW  - Leukemia, Myeloid, Acute
KW  - fms-Like Tyrosine Kinase 3
KW  - Antineoplastic Agents
KW  - Protein Kinase Inhibitors
KW  - Concurrent Review
TI  - FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives
DO  - 10.23736/S0026-4806.20.06989-X
T2  - Minerva Medica
M2  - 427
KW  - IDIS
KW  - CHUS
KW  - Inhibidor FLT3
VL  - 111
ER  -